Hanmi Pharmaceutical's obesity drug 'Efe' reportedly receives South Korean regulator approval

A social post claims Hanmi Pharmaceutical's obesity drug 'Efe' has received approval from South Korea's food and drug regulator (식약처). The post says Efe's 40-week average weight-loss rate in approval data is 9.02%, lower than Wegovy's 14.9% and Mounjaro's up to 20.9%, and argues its edge lies in price, side effects and supply stability.

Detected & updated continuously · Source: Nebula